Avid Bioservices

53Biologics, a Spanish CDMO, won the Biotechforum Award for 'Best Company in Biotechnology Innovation' at Farmaforum, highlighting its work in microbial expression systems. The company, known for its end-to-end drug development support, has expanded its GMP microbial manufacturing line to meet global demand.

Samsung Biologics launched S-HiCon™, a high-concentration formulation platform for stable liquid formulations up to 200 mg/mL, addressing viscosity and protein aggregation challenges in biopharmaceutical development.

Enzene launches EnzeneX 2.0, an evolved FCCM platform for biologics, at CPHI Milan 2024, promising 50% cost reduction and 40 kg/kL batch at $40/g by 2025, with a new $50M NJ facility.

Lifecore Biomedical, Inc. (NASDAQ: LFCR) will report Q1 FY2025 financial results on Oct 4, 2024, prior to market open, hosting a webcast at 8:30 a.m. ET. The webcast will discuss Q1 financial results and recent corporate developments. Visit https://ir.lifecore.com/events-presentations for live and archived webcasts.

PCI Pharma Services invests over $365 million in new and expanded facilities in Europe and North America for advanced drug delivery systems, focusing on injectable formats. The investment includes a 545,000-square-foot expansion in Rockford, Illinois, and a new facility near Dublin, Ireland, both set to enhance PCI's capabilities in drug-device combination products from clinical to commercial stages.

PCI Pharma Services is investing over $365 million in global infrastructure for advanced drug delivery systems, focusing on injectable formats. This includes expansions in Europe and North America, with a 545,000-square-foot facility in Rockford, Illinois, and a 70,000-square-foot expansion in Europe. PCI aims to manage the full lifespan of drug-device combination products, from development to commercialization, with new facilities in Dublin, Ireland, supporting large-scale temperature-controlled storage and commercial-scale packaging operations.

The Biotechnology Contract Manufacturing Market is projected to grow from $16.28 Bn in 2023 to $31.05 Bn by 2031, driven by increasing demand for biopharmaceuticals, rising R&D investments, and advancements in bioprocessing technologies. Key drivers include the use of biologics in various therapeutic areas and the demand for personalized medicine. Challenges include high manufacturing costs, regulatory compliance, and intellectual property risks. Prominent players include Lonza, Samsung Biologics, and Thermo Fisher Scientific.

MilliporeSigma launches Mobius ADC reactor, a scalable single-use mixer for antibody drug conjugate (ADC) manufacturing, reducing cross-contamination risks and speeding up production. The reactor uses Ultimus Film technology for enhanced durability and leak resistance, addressing common biomanufacturing pain points.

The North America CMO and CDMO biotechnology market is robust, segmented by applications like oncology, cardiology, immunology, neurology, and metabolic diseases. Key manufacturers include Patheon, Catalent, Samsung Biologics, and Lonza. The market is driven by technological advancements and growing demand for automation, with a promising future for innovation and growth.